Acute pulmonary thromboembolism remains a significant cause of morbidity and mortality worldwide. Its diagnosis, risk stratification and early treatment are essential. The mainstay of treatment is anticoagulation.
* Several studies show that transcatheter aortic valve replacement (TAVR) benefits patients with aortic stenosis, but persistent fibrosis and myocardial hypertrophy can lead to worse outcomes.
* This study aimed to investigate the effects of renin-angiotensin system (RAS) inhibitors on heart remodeling and clinical outcomes after TAVR in patients with severe aortic stenosis.
* The results demonstrated that RAS inhibitor treatment was linked to reduced left ventricular hypertrophy, lower cardiovascular mortality at three years, and fewer incidents of new atrial fibrillation and cerebrovascular events.